Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Precision Medicine in Systemic Mastocytosis.
Nicolosi M, Patriarca A, Andorno A, Mahmoud AM, Gennari A, Boldorini R, Gaidano G, Crisà E. Nicolosi M, et al. Among authors: crisa e. Medicina (Kaunas). 2021 Oct 20;57(11):1135. doi: 10.3390/medicina57111135. Medicina (Kaunas). 2021. PMID: 34833353 Free PMC article. Review.
Atypical Chronic Myeloid Leukemia: Where Are We Now?
Crisà E, Nicolosi M, Ferri V, Favini C, Gaidano G, Patriarca A. Crisà E, et al. Int J Mol Sci. 2020 Sep 18;21(18):6862. doi: 10.3390/ijms21186862. Int J Mol Sci. 2020. PMID: 32962122 Free PMC article. Review.
Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: evidence for premature aging of the myeloid compartment.
Lobetti-Bodoni C, Ferrero D, Genuardi E, Passera R, Bernocco E, Sia D, Grignani G, Crisà E, Monitillo L, Rocci A, Drandi D, Giai V, Zanni M, Boi M, Isaia G, Barbero D, Lunghi M, Abruzzese E, Radaelli F, Pini M, Pregno P, Carlo-Stella C, Gaidano G, Boccadoro M, Ladetto M. Lobetti-Bodoni C, et al. Among authors: crisa e. Mech Ageing Dev. 2012 Jul;133(7):479-88. doi: 10.1016/j.mad.2012.05.007. Epub 2012 Jun 9. Mech Ageing Dev. 2012. PMID: 22687638 Clinical Trial.
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS).
Oliva EN, Riva M, Niscola P, Santini V, Breccia M, Giai V, Poloni A, Patriarca A, Crisà E, Capodanno I, Salutari P, Reda G, Cascavilla N, Ferrero D, Guarini A, Tripepi G, Iannì G, Russo E, Castelli A, Fattizzo B, Beltrami G, Bocchia M, Molteni A, Fenaux P, Germing U, Ricco A, Palumbo GA, Impera S, Di Renzo N, Rivellini F, Buccisano F, Stamatoullas-Bastard A, Liberati AM, Candoni A, Delfino IM, Arcadi MT, Cufari P, Rizzo L, Bova I, D'Errigo MG, Zini G, Latagliata R. Oliva EN, et al. Among authors: crisa e. J Clin Oncol. 2023 Oct 1;41(28):4486-4496. doi: 10.1200/JCO.22.02699. Epub 2023 Jun 9. J Clin Oncol. 2023. PMID: 37294914 Free PMC article. Clinical Trial.
Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study.
Kizilors A, Crisà E, Lea N, Passera R, Mian S, Anwar J, Best S, Nicolini FE, Ireland R, Aldouri M, Pocock C, Corbett T, Gale R, Bart-Smith E, Weston-Smith S, Wykes C, Kulasekararaj A, Jackson S, Harrington P, McLornan D, Raj K, Pagliuca A, Mufti GJ, de Lavallade H. Kizilors A, et al. Among authors: crisa e. Lancet Haematol. 2019 May;6(5):e276-e284. doi: 10.1016/S2352-3026(19)30027-4. Lancet Haematol. 2019. PMID: 31036317
Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice.
Clavio M, Crisà E, Miglino M, Guolo F, Ceccarelli M, Salvi F, Allione B, Ferrero D, Balleari E, Finelli C, Poloni A, Selleri C, Danise P, Cilloni D, Di Tucci AA, Cametti G, Freilone R, Fanin R, Bigazzi C, Zambello R, Crugnola M, Oliva EN, Centurioni R, Alesiani F, Catarini M, Castelli A, Abbadessa A, Capalbo SF, Musto P, Angelucci E, Santini V. Clavio M, et al. Among authors: crisa e. Cancer. 2021 Jun 15;127(12):2015-2024. doi: 10.1002/cncr.33472. Epub 2021 Mar 19. Cancer. 2021. PMID: 33739457 Free article.
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML.
Tiribelli M, Latagliata R, Breccia M, Capodanno I, Miggiano MC, Cavazzini F, Bucelli C, Attolico I, Crescenzi SL, Russo S, Annunziata M, Sorà F, Bonifacio M, Mulas O, Loglisci G, Maggi A, Binotto G, Crisà E, Scortechini AR, Leporace AP, Sancetta R, Murgano P, Abruzzese E, Stagno F, Rapezzi D, Luzi D, Vincelli I, Bocchia M, Fava C, Malato A, Crugnola M, Pizzuti M, Lunghi F, Galimberti S, Dalmazzo M, Fanin R, Scalzulli E, Foà R, Iurlo A, Saglio G, Specchia G. Tiribelli M, et al. Among authors: crisa e. Cancer. 2023 Sep 1;129(17):2637-2644. doi: 10.1002/cncr.34923. Epub 2023 Jun 24. Cancer. 2023. PMID: 37354090
45 results